Arcutis Biotherapeutics, Inc. (ARQT) vs Edgewise Therapeutics, Inc. (EWTX)
- Arcutis Biotherapeutics, Inc. ARQT 28.82 −0.96%
- Edgewise Therapeutics, Inc. EWTX 37.19 −2.64%
Arcutis Biotherapeutics, Inc. and Edgewise Therapeutics, Inc. are both Biotechnology companies. Edgewise Therapeutics, Inc. is the larger, with a market value of $4.2B against $3.7B — 1.1× the size. Edgewise Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 131×. Arcutis Biotherapeutics, Inc. has the higher net margin (6.15% vs 0.00%) and the higher return on invested capital (23.6% vs 0.00%). Across the 14 metrics below, Arcutis Biotherapeutics, Inc. leads on 10 and Edgewise Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | ARQT | EWTX | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.14% | 0.00% | 65.16% |
| Operating margin | 7.38% | 0.00% | 0.00% |
| Net margin | 6.15% | 0.00% | 0.00% |
| Free cash flow margin | 8.42% | 0.00% | 0.00% |
| Return on equity | 15.86% | (38.03%) | (56.36%) |
| Return on assets | 6.78% | (36.09%) | (48.04%) |
| Return on invested capital | 23.62% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack